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The use of advanced proteomics approaches in the search for biomarkers in chronic lung
diseases, such as asthma and COPD, is rather limited. Asthma and COPD are complex dis-
orders, which can be subdivided into several phenotypes. This results in a heterogeneity of
differential expressed biological molecules. Furthermore, genetic differences between ani-
mals and humans make ‘translation’ of possible biomarkers challenging. Yet, the improved
sensitivity and high throughput of proteomic techniques could be an important asset for
(new) protein biomarker discovery in either human or animal models. We  have reviewed the
literature that reported the use of different proteomics approaches performed on samples
obtained from humans and murine models in asthma and COPD research for the discovery
of  new biomarkers of diseases, biomarkers of sensitization or for the reﬁnement of treat-
ment. There is an increasing trend in the use of proteomics to explore new biomarkers of
asthma or COPD. Although several murine models have been developed to study these lungnimal models diseases, and proteomics studies have been performed, ‘translation’ of identiﬁed candidate
biomarkers into clinical studies is often lacking.
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1.  Introduction
A rapid increase in the use of proteomics in different research
domains such as cancer, invertebrate immunology and plant
physiology was made possible thanks to the completion
of several genomes, technical advances in instrumentation
(increased sensitivity) and methods (puriﬁcation, separation,
identiﬁcation) and the development of new bioinformatical
tools [1–5]. In 2013, almost 5000 papers were published using
a proteomics technique (Pubmed search: Publication date: 2013;
Keyword: Proteomics).  Yet, the use of advanced proteomics
approaches in the search for biomarkers in chronic lung dis-
eases, such as asthma and COPD, is rather limited. This
limitation is attributable to multiple factors. First, asthma
and COPD are complex disorders which are subdivided into
several phenotypes [6–8]. This heterogeneity results in dif-
ferential expression of biological effector molecules, namely
proteins and peptides. Moreover, human samples are inher-
ently characterized by a larger heterogeneity as compared to
murine samples due to a different genetic background. Finally,
ethically and practically, it is not feasible to obtain large num-
bers of human samples hampering large proteomic studies
[9].
Nevertheless, the sensitivity and high throughput of
proteomics techniques could be useful to discover (new)
biomarker proteins in humans or animal models, previously
not associated with a disease phenotype, at a time point
much earlier than current existing diagnostic tools can do [10].
Despite efforts to develop animal models to model different
human diseases, translation of (proteomics) research evidence
from animals to humans is difﬁcult and time consuming. Only
one out of three animal studies evaluating medical interven-
tions for human diseases have been replicated in clinical trials
with an average time span of seven years to complete the
translation from animals to humans [11].
We have reviewed the literature that reported the use
of different proteomics approaches performed on samples
obtained from humans and murine models in asthma and
COPD research for the discovery of new biomarkers of dis-
eases, biomarkers of sensitization or for the reﬁnement of
treatment.
Asthma affects more  than 300 million people worldwide,
whereas COPD is predicted to be the third most leading cause
of death by 2030 (WHO; www.who.int).
Asthma, characterized by a reversible airway obstruction,
a non-speciﬁc airway hyperreactivity and an airway inﬂam-
mation, is orchestrated by the interplay of numerous cells,
from both the innate immune system (e.g. dendritic cells,
macrophages, mast cells, eosinophils and neutrophils) and. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
the adaptive immune system (T cells and B cells) [12–14].
Clinical manifestations of asthma are episodic wheezing,
coughing, shortness of breath and non-speciﬁc hyperreac-
tivity to e.g. cold air or cigarette smoke. Asthma can be
subdivided in different classes (allergic asthma, non-allergic
asthma, occupational asthma, etc.). Although different phe-
notypes of asthma have already been distinguished, the
exact molecular mechanisms underlying the disease remain
unclear [14].
Chronic obstructive pulmonary disease (COPD) is charac-
terized by a progressive airﬂow limitation that is partially
reversible, a chronic lung inﬂammation and systemic effects
[6]. Although the main risk factor to develop COPD is smoking
tobacco, with more  than 90% of COPD patients having a smok-
ing history, other factors such as maternal smoking, childhood
asthma and outdoor air pollution have recently been associ-
ated with the development of COPD [15].
The prevalence of both asthma and COPD is increased dur-
ing the last decades, indicating that current state-of-the art
techniques for diagnosis and management are suboptimal
[16]. Current diagnostic tools such as spirometry fail to pin-
point the early onset of chronic lung diseases resulting in late
diagnosis when adverse clinical symptoms have already been
established. Moreover, the few existing molecular markers
lack in sensitivity and speciﬁcity (e.g. nitric oxide, eosinophil
cationic protein and eosinophil peroxidase) [16,17].
2.  Proteomics  approaches  in  asthma  and
COPD
Clinically, it has been estimated that almost 10% of the
genome is directly involved in disease pathogenesis. There-
fore, detecting distinct protein biomarkers, encoded by the
genome, in certain pathologies can contribute to disease
detection, monitoring disease progression and response to
treatment [18].
So far, most proteomic studies performed in either patient
cohorts or murine models of asthma and COPD have inves-
tigated established disease (Tables 1 and 2). Several of the
differentially expressed proteins in these studies, could be
linked with hallmarks of allergic asthma such as airway hyper-
reactivity, lung inﬂammation [19–21] and remodeling [22–24].
Proteomic changes due to long term cigarette smoke expo-
sure in murine models could be related to lung damage and
smoke-induced lung irritation [25,26]. Proteomic screening in
humans suffering from COPD most often focused on samples
obtained from the respiratory system, such as bronchoalveo-
lar lavage (BAL), lung tissue or cells, epithelial lining ﬂuid or
induced sputum. Some studies have also analyzed potential
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Table 1 – Overview of proteomics studies in animal models of asthma and COPD.
Reference Species Disease Inducer Intervention Sample Technique Main ﬁndings Up/downa
Houtman et al. [42] Mouse Non-allergic
asthma
DNFB Lung 2D-GE
Silver staining
Coronin 1A
Vinculin
Gelsolin
↑
↑
↓
Roh et al. [43] Mouse Allergic asthma OVA DMS Lung 2D-GE
Silver staining
T  complex polypeptide 1
EH-domain containing protein 4
Plasminogen
↑
↓
↓
Signor et al. [19] Rat Allergic asthma OVA Endotoxin BAL 2D-GE
Coomassie
staining
Fetuin A
Fetuin B
Haptoglobin
Clara cell 10 kDa secretory protein
↑
↑
↑
↓
Jeong et al. [45] Mouse Allergic asthma OVA Lung 2D-GE
Coomassie
staining
Chitinase 3-like 3
Chitinase 3-like 4
↑
↑
Zhao et al. [60] Mouse Allergic asthma OVA BAL 2D-GE
Silver staining
Lungkine
Chitinase 3-like 3
Chitinase 3-like 4
Calcium-activated chloride channel regulator 1
↑
↑
↑
↑
Greenlee et al. [50] Mouse
MMP2−/−
MMP9−/−
Allergic asthma OVA BAL 2D-DIGE Chitinase 3-like 3
Calgranulin A
↑
↑
Zhao et al. [36] Mouse Allergic asthma OVA DMS BAL 2D-GE
Silver staining
Chitinase 3-like 3
Chitinase 3-like 4
Vitamin D binding protein
Hemopexin
↓
↓
↑
↓
Liu et al. [61] Mouse Allergic asthma OVA Salbutamol Lung 2D-GE
Silver staining
Rho GDP-dissociation inhibitor 2
Peroxiredoxin 5
↑
↑
Zhang et al. [25] Rat COPD Cigarette
smoke
Lung  2D-GE
Coomassie
staining
Thioredoxin
Peroxiredoxin 6
-Enolase
↑
↑
↓
Calvo et al. [23] Mouse Allergic asthma OVA Lung SELDI-TOF MS Found inﬂammatory zone 1
Calcyclin
Clara cell 10 kDa secretory protein
↑
↑
↑
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Table 1 (Continued)
Reference Species Disease Inducer Intervention Sample Technique Main ﬁndings Up/downa
Xu et al. [26] Rat COPD Cigarette
smoke
Radon
Lung  2D-GE
Coomassie
staining
RAGE
Thioredoxin
Calcyclin
↑
↑
↑
Haenen et al. [20] Mouse Occupational
asthma
TDI Aur LN
BAL
Serum
2D-DIGE Lymphocyte speciﬁc protein 1
Vitamin D binding protein
Hemopexin
↓
↑
↑
Calvo et al. [24] Mouse Allergic asthma OVA Lung 2D-DIGE 78 kDa glucose-regulated protein precursor ↑
Tewari et al. [35] Mouse COPD Cigarette
smoke
Plasma  2D-DIGE Fibrinogen
-1-antitrypsin
Arginase
↓
↑
↓
Louten et al. [21] Mouse
Macaque
TSLP Tg mice –
HDM
BAL
BAL
1D-GE
LC-MS/MS
Chitinase  3-like 3
Chitinase 3-like 4
Cyclophilin A
Coﬁlin A
↑
↑
↑
↑
Haenen et al. [41] Mouse Occupational
asthma
TDI Aur LN
Serum
2D-DIGE
Coronin 1a
Lymphocyte speciﬁc protein 1
Hemopexin
1  sens
↑
−
↑
2  sens
↑
↓
↓
a Differences presented are always comparisons from a certain disease vs. healthy (e.g. asthma vs. control).
Identiﬁcation of differentially expressed proteins was performed via mass spectrometry (MALDI-TOF MS or tandem mass spectrometric analysis).
Abbreviations: 1D-GE, one-dimensional gel electrophoresis; 2D-GE, two-dimensional gel electrophoresis; 2D-DIGE, two-dimensional difference gel electrophoresis; Aur LN, auricular lymph nodes;
BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease; DMS, dexamethasone; DNFB, dinitroﬂuorobenzene; EH-domain, epidermal growth factor receptor substrate 15; HDM,
House Dust Mite; LC–MS/MS, liquid chromatography mass spectrometry; MMP, matrix metalloproteinase; OVA, ovalbumin; RAGE, receptor for advanced glycation endpoints; SELDI-TOF MS, surface
enhanced laser desorption/ionization – time of ﬂight mass spectrometry; sens, sensitization; TDI, toluene-2,4-diisocyanate; TSLP Tg, thymic stromal lymphopoietin trangenic.
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Table 2 – Overview of proteomics studies in human asthma and COPD.
Reference Disease Sample Technique Main ﬁndings Up/downa
Merkel et al. [28] COPD BAL SELDI-TOF MS Neutrophil defensin 1
Neutrophil defensin 2
Calgranulin A
Calgranulin B
Clara cell phospholipid-binding protein
↑
↑
↑
↑
↓
Candiano et al. [44] Allergic asthma Bronchial epithelial
cells (IL-4 stimulated)
BAL
2D-GE
Coomassie staining
Gelsolin (45 kDa)
Gelsolin (85 kDa)
Gelsolin (45 kDa) after allergen challenge
Gelsolin (85 kDa) after allergen challenge
↑
↑
=
↓
Steiling et al. [29] COPD Bronchial epithelial
cells
1D-GE
LC–MS/MS
PLUNC
Clara  cell 10 kDa secretory protein
Prolyl 4-hydroxylase beta subunit
↓
↓
↑
Larsen et al. [62] Mild asthma BAL 2D-GE
Coomassie or silver staining
Haptoglobin ↑
Larsen et al. [46] Mild asthma
Scleroderma (SSc)
Fibroblasts cultured
in BAL & bronchial
biopsies
2D-GE
Coomassie or silver staining
Alpha-smooth muscle actin ↑
Jeong et al. [47] Allergic asthma Peripheral T
lymphocytes
2D-GE
Silver staining
Phosphodiesterase 4
Thioredoxin 2
Glutathione S transferase M3
↑
↑
↓
Ohlmeier et al. [48] COPD BAL 2D-GE
Silver  staining
Surfactant protein A ↑
Gray et al. [27] Allergic asthma
COPD
CF
Sputum SELDI-TOF MS Calgranulin A, B & C
Clara cell 10 kDa secretory protein
Proline rich salivary peptide
↑
↓
↓
Wu et al. [22] Allergic asthma BAL after segmental
airway challenge
LC–MS/MS Matrix metalloproteinase-9
Calgranulin B
Tissue inhibitor of metalloproteinases 1
↑
↑
↑
Bandow et al. [63] COPD Plasma 2D-GE
Sypro Ruby
Plasma retinal-binding protein
Glutathione peroxidase 1
Fibrinogen
Apolipoprotein E
↓
↑
↑
↑
Bozinovski et al. [64] COPD Serum SELDI-TOF MS Serum amyloid A ↑
Hur et al. [37] Occupational asthma BAL 2D-GE
Coomassie staining
Ferritin
Transferrin
↓
↑
Lee et al. [33] COPD Lung tissue 2D-GE
Silver staining
Matrix metalloproteinase 13
Thioredoxin-like 2
↑
↑
Gomes-Alves et al. [65] Allergic asthma
COPD
CF
Serum
Nasal epithelial cells
SELDI-TOF MS Biomarker signatures, one signiﬁcant identiﬁcation, hemoglobin
subunit beta (↑ in CF as compared to asthma & control)
Bloemen et al. [58] Allergic asthma EBC LC–MS/MS Proteolytic peptide proﬁles discriminate between healthy vs. asthma.
No identiﬁcations so far
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Table 2 (Continued)
Reference Disease Sample Technique Main ﬁndings Up/downa
Gharib et al. [59] Allergic asthma Sputum LC–MS/MS Calgranulin A
Calgranulin B
↓
↓
Hu et al. [32] COPD Lung tissue 2D-GE
MALDI-TOF MS
Heat shock protein 27
Cyclophilin A
↑
↑
Ohlmeier et al. [66] COPD Sputum 2D-DIGE Polymeric immunoglobulin receptor ↑
Verrills et al. [34] COPD
Allergic asthma
Plasma 2D-DIGE 2-macroglobulin
haptoglobin
ceruloplasmin
hemopexin
↓
↑
↓
↓
Alexandre et al. [56] COPD Erythrocyte
membrane proteins
O16/O18 labeling
LC–MS/MS
Chorein
Methemoglobin reductase
↓
↓
Franciosi et al. [31] COPD Epithelial lining ﬂuid iTRAQ
2D-LC–MS/MS
MALDI-TOF/TOF MS
Lactotransferrin
Coﬁlin-1
HMGB1
Alpha 1-antichymotrypsin
↑
↑
↓
↑
Lee et al. [67] Uncontrolled asthma Sputum 2D-GE
Coomassie staining
S100 calcium binding protein A9 ↑
Merali et al. [68] COPD Plasma 1D-GE
LC–MS/MS
Glucose regulated protein 78
Soluble hemoglobin scavenger receptor
IL-1 receptoraccessory protein
Macrophage stimulatory protein
↑
↓
↑
↑
Pastor et al. [30] COPD BAL 2D-GE
Sypro Ruby
Peroxiredoxin 1
Heat shock protein 70
Pyruvate kinase 2
↑
↑
↑
Tu et al. [69] COPD BAL LC–MS/MS Alcohol dehydrogenase 1B
Aldehyde dehydrogenase family 3A1
Aldehyde dehydrogenase (mitochondrial)
↑
↑
↑
a Differences presented are always comparisons from a certain disease vs. healthy (e.g. asthma vs. control).
Identiﬁcation of differentially expressed proteins was performed via mass spectrometry (MALDI-TOF MS or tandem mass spectrometric analysis).
Abbreviations: 2D-GE, two-dimensional gel electrophoresis; 2D-DIGE, two-dimensional difference gel electrophoresis; BAL, bronchoalveolar lavage; CF, cystic ﬁbrosis; COPD, chronic obstructive
pulmonary disease; EBC, exhaled breath condensate; LC–MS/MS, liquid chromatography mass spectrometry; PLUNC, palate, lung and nasal epithelium carcinoma associated protein precursor;
SELDI-TOF MS, surface enhanced laser desorption/ionization – time of ﬂight mass spectrometry; SSc, systemic sclerosis.
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abundance of the peptide in the different conditions can bee u  p a o p e n p r o t e o m i
rotein biomarkers in blood derived samples (plasma, serum
r erythrocytes). These human proteomic studies revealed
igniﬁcant changes in proteins involved in the regulation of
nﬂammation [27–29], oxidative stress [30–32], the acute phase
nd immune response [31–35] and structural proteins [31,33].
he highlighted proteins in all these studies could be deﬁned
s markers of established disease. They are, however, less
uited for the detection of early disease onset [16].
The inﬂuence of steroid treatment (dexamethasone) on
he proteome proﬁle of BAL ﬂuid obtained from murine mod-
ls, has also been investigated. The level of several proteins,
nown to be upregulated in allergic asthma, such as chitinase
-like 3 (Ym1), chitinase 3-like 4 (Ym2) and surfactant pro-
ein D were decreased after dexamethasone treatment [36].
outen et al. [21], using a transgenic mouse model which spon-
aneously develops asthma, conﬁrmed some of the results. In
his study, Ym1  and Ym2  were upregulated both at the protein
nd mRNA  level, comparing control versus asthmatic mice.
fter dexamethasone treatment, Ym1  mRNA  levels decreased
hereas Ym2 mRNA  levels were not affected by the treat-
ent.
Although most studies have been performed in established
llergic asthma (or COPD), a reasonable subset of asthma
9–15%) is attributable to occupational exposures (e.g. ani-
al  derived proteins, ﬂour, chemicals, etc.). Only few studies
ave investigated proteomic changes in occupational asthma.
ne study by Hur et al. [37] detected signiﬁcant differences
n ferritin and transferrin levels in BAL ﬂuid and serum of
iphenylmethane diisocyanate (MDI) asthmatic workers com-
ared to MDI-exposed asymptomatic workers and non-atopic
ealthy controls. Unfortunately, these results were not con-
rmed in a more  recent study by Sastre et al. [38], investigating
orkers exposed to toluene diisocyanate (TDI). In one of our
tudies, we found changes in the levels of ferritin and trans-
errin in BAL ﬂuid of TDI-asthmatic mice, as shown by Hur
t al. The discrepancy between the results obtained by Hur
t al. and Sastre et al. concerning biomarkers of diisocyanate
sthma are currently a matter of debate since clinical cross-
eactivity between diisocyanates (TDI and MDI) is suggested
o be common [39]. Moreover, both the study of Hur et al.
nd Sastre et al. used populations with similar character-
stics, although Hur et al. had a considerably larger group
f asymptomatic and healthy controls compared to Sastre
t al.
Asthma phenotypes share commonalities in their pathol-
gy such as oxidative stress, inﬂammation and non-speciﬁc
irway hyperreactivity. Nevertheless, some of the proteins
uch as peroxiredoxins and enolases, are commonly identi-
ed regardless of the studied pathology, implying that caution
hould be taken when attributing the term ‘biomarker’ to a
ertain protein [40].
So far, proteomic studies conducted in pulmonology have
nvestigated changes in the proteome of healthy subjects
ersus diseased individuals (asthma, COPD, etc.) using sam-
les from either animal models or patients. Results from a
tudy of our own group in a mouse model of chemical-induced
sthma, show that already after two sensitizations, substan-
ial differences occur in the proteome, which we presume
elate to the onset of an immune response leading to asthma
41]. ( 2 0 1 4 ) 101–112 107
3.  Methodology
Most often 2D-gel electrophoresis (2D-GE) combined with
silver or Coomassie staining and a software package, has
been used to separate, visualize and analyze differences
in protein levels between healthy and diseased subjects
(Tables 1 and 2) [26,36,37,42–48]. This is followed by peptide
mass ﬁngerprinting or tandem mass spectrometry analysis
for the identiﬁcation of the proteins. The major drawbacks
of silver and Coomassie staining are the small linear dynamic
range along with the high need for many  technical and biolog-
ical replicates – to correct for the variation between different
stained gels – as well as the limited sensitivity of these meth-
ods.
The introduction of two-dimensional difference gel elec-
trophoresis (2D-DIGE) has overcome these shortcomings and
is now the gold standard among gel-based differential pro-
teomics techniques [49]. This ﬂuorescence-based technique
allows the use of multiplexed samples with an inter-
nal standard that virtually eliminates gel-to-gel variability,
increasing the conﬁdence that uncovered differences are due
to real changes, rather than inherent biological variation
or experimental variability. Some recent studies in non-
malignant lung diseases have applied 2D-DIGE rather than the
less preferred silver staining method [20,24,50]. Although 2D-
DIGE revolutionized differential analysis in proteomics, this
gel-based technique also has some inherent limitations. Par-
ticularly, proteins present in extremely low concentrations or
proteins that cannot be separated via gel-based techniques
due to their physicochemical properties (iso-electric point,
hydrophobicity, molecular weight) will not be detected [51,52].
Membrane bound proteins such as surface markers, which
could be important in the development of asthma and COPD,
are not resolved via gel-based proteomics techniques due to
their hydrophobic nature.
Several gel-free proteomics technologies were developed
to overcome these limitations. Surface enhanced laser des-
orption/ionization mass spectrometry (SELDI-TOF) is suited
to directly proﬁle subsets of smaller proteins (<20 kDa) based
on their physicochemical properties (hydrophobic, metal-
binding, etc.) [23,27], however the poor resolution often
hampers identiﬁcation of the proteins.
In other gel-free methods, a protein mixture is enzymati-
cally cleaved into peptides, and subsequently these peptides
are separated and identiﬁed using liquid chromatography and
tandem mass spectrometry (LC–MS/MS) [58,59]. Relative quan-
titation can be derived by direct comparison of ionic signals
produced by peptides in parallel LC–MS analyses. This label-
free method uses statistical tools to identify peptides that
express consistent differences between samples across mul-
tiple runs.
An alternative for relative quantitative analysis is tag-
ging the peptides with chemically almost identical labels
that have a mass difference (isotopes). The samples are then
combined and analyzed together using LC–MS. The relativecalculated from the ratio of the peak intensity of the differ-
ent isotopic forms [53]. Isobaric tags for relative and absolute
quantiﬁcation (iTRAQ) is based on covalent labeling of the
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N-terminus and side chain amines of peptides from protein
digestions with tags of varying mass. Combined with high
resolution LC–MS/MS iTRAQ allows the quantitative compari-
son of protein levels. Franciosi et al. [31] successfully applied
this technique in epithelial lining ﬂuid of COPD patients and
non-COPD controls and found signiﬁcantly different levels
of lactotransferrin, high-mobility group protein B1, alpha 1-
antichymotrypsin and coﬁlin-1. Stable isotopic labeling by
amino acids in cell culture (SILAC) involves the metabolic
incorporation of ‘normal’ or ‘heavy’ forms (C13 or N15) of
arginine or lysine, supplied in culture medium, in newly syn-
thetized proteins. The normal and heavy forms of the peptides
appear as two  distinct peaks in MS  and relative quantitation is
achieved by comparing the signal intensities. SILAC has been
successfully used in studies focusing on lung cancer [54,55].
Alexandre et al. [56], used differential oxygen (O16/O18) label-
ing to quantify differences in erythrocyte membrane proteins
of COPD patients compared to healthy controls. Differential
O16/O18 labeling occurs at the C-terminal carboxyl group of
peptides, derived from the proteolytic digestion of proteins,
where two O16 atoms are replaced by O18 atoms. The result-
ing mass shift permits the relative quantitation of proteins
between two conditions [57].
These gel-free methods also have their inherent limita-
tions. A typical tissue extract contains a few thousands of
proteins that after digestion will result in a more  complex
peptides mixture, while the number of peptides that can be
identiﬁed due to co-elution and ion suppression is limited
[58]. Posttranslational modiﬁcations such as phosphoryla-
tions, often important in the regulation of protein function,
will be visualized on 2D gels by different spots as a result of
shift in isoelectric point (pI). In gel-free proteomics, pI infor-
mation, together with protein molecular weight information,
is lost.
4.  Mice  vs.  men
One can debate if human samples are preferable over samples
obtained from mouse models. Nonetheless, signiﬁcant under-
standing on the pathogenesis of asthma and COPD has been
derived from animal experiments, particularly in mice and
rats [25,26,70]. Several mouse speciﬁc immunological tools
and the availability to use transgenic mice (e.g. TSLSP Tg mice)
favor this species [21]. Moreover, 99% of mouse genes have
homologues in humans, facilitating proteomics approaches
[71]. Also, ethical and moral  issues prevent profound mech-
anistic investigations in humans [72]. Animals are generally
kept in clean animal houses, limiting the environmental fac-
tors to which they are exposed and facilitate the exposure to
exact concentrations of a known substance (e.g. allergen or
tobacco smoke) [73]. In animals, invasive samples, such as
lung tissue, lymphoid tissue and BAL ﬂuid are more  easily
obtained than in humans.
Unfortunately, the results obtained from animal exper-
iments cannot directly be extrapolated to humans since
important differences in airway morphology and development
exist between mice and humans. Moreover, the initiation,
development and responses of the innate and adaptive
immune system differ substantially between mice and men 4 ( 2 0 1 4 ) 101–112
[74]. No mouse model is currently available that matches
all phenotypic characteristics of human asthma [75–77], nor
COPD [78]. Most mouse models are an acute model of asthma,
lacking chronicity and airway remodeling, two characteris-
tics of human asthma. The choice of mouse strain has also
been demonstrated to have an inﬂuence on the physiological
parameters (cytokines, neutrophils, eosinophils, etc.) [79–81].
Yet, it is possible to induce several characteristics of the dis-
ease such as lymphocyte activation and IgE production, along
with airway hyperresponsiveness, airway inﬂammation and
in some studies airway remodeling [24,82–87].
Bearing in mind these shortcomings, animal models can
be seen as a platform to generate and test hypotheses which
need validation in humans [88]. Despite the signiﬁcant results
obtained from animal studies, translation to human disease is
difﬁcult and time consuming. Hackam et al. [11] have reviewed
highly cited animal studies, showing that only one out of three
animal studies evaluating medical interventions for human
diseases have been replicated in clinical trials.
5.  Sample  origin
Another important issue concerns the best choice of tissue
for analysis. So far, lung tissue has been the most used sam-
ple in murine models of asthma and COPD for obvious reasons
[23,24,26,42,43,45,89]. In animals, it is possible to obtain sam-
ples requiring more  invasive techniques and, moreover, lung
tissue will possibly contain high concentrations of potential
biomarkers speciﬁc for lung diseases. Nevertheless, study-
ing proteome changes in lung tissue by gel-based techniques
is limited to the soluble proteins. It is important to validate
the biomarkers obtained in lung tissue, using more  acces-
sible samples, such as BAL ﬂuid and to see how well data
of both compartments are correlated [90]. BAL ﬂuid provides
the most faithful reﬂection of the protein composition of the
pulmonary lumen and is therefore the preferred sample in
humans [91–93]. However, proteomic analysis of BAL ﬂuid is
complicated by a low protein abundance and high salt con-
tent and possible contamination by serum proteins, as a result
from leakage during lung inﬂammation [94]. Although serum
proteins in BAL could also reﬂect the current pulmonary situ-
ation, albumin and immunoglobulin depletion strategies have
been developed and applied to improve the quality of pro-
teomic studies [20].
Recently, in humans, the use of less invasive techniques
such as induced sputum and exhaled breath condensate (EBC)
have also been evaluated [27,58]. Induced sputum and EBC can
be routinely collected from patients during follow-up, but the
use of these samples in proteomics studies is scarce due to
the very low protein content and needs to be optimized.
Strikingly, only few of the studies listed in Tables 1 and 2
used plasma or serum samples [20,41,63,64]. Serum is an ideal
biological sample that contains an archive of information due
to the presence of a variety of proteins released by diseased tis-
sue [95]. Nevertheless, proteomic analysis of serum has several
advantages and disadvantages. Serum is easy to acquire, can
be obtained at different time points (e.g. during follow-up) and
has a high protein content. However, high-abundant proteins
(albumin, IgG and transferrin) can possibly mask potential
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iomarkers with a relative low abundance, and serum is also
ighly variable [96].
It seems that the samples with the highest protein content
how fewer signiﬁcant differential proteins, giving the impres-
ion that the complexity reduces the sensitivity. Therefore,
nrichments of subsets of cells, such as T- and B-lymphocytes,
r macrophages and leucocytes, could reduce the complexity
nd facilitate proteomic analysis. On the other hand, a lot of
tarting material (cfr. mice) is required to have enough cells to
erform these experiments, which is a major limiting factor.
n humans, this can be overcome because a large amount of
lood can be sampled to isolate speciﬁc lymphocyte subsets,
s done by Jeong et al. [47], who compared human peripheral
-lymphocytes from asthma patients and healthy controls.
.  Interpretation  of  results
ost often, the end-result of a proteomic study is the identiﬁ-
ation of ten to hundreds of differentially expressed proteins
hich are presented in a table. A few of these proteins are
elected based on literature and biological relevance. Several
roteins, such as annexins, peroxiredoxins and haptoglobins,
re differentially expressed in different studies when compar-
ng all the results of the papers described in Tables 1 and 2.
ne should question if these proteins could be called biomark-
rs since these proteins are repeatedly identiﬁed throughout
ifferent research domains and are therefore called ‘déjà-vu’-
roteins [40]. Chitinase 3-like 3 (Ym1) and Chitinase 3-like
 (Ym2) are both members of the chitinase family, respon-
ible for the degradation of chitin which is present in the
xoskeleton of arthropods and in cell membranes of fungi.
lthough chitin is not present in mammalians they are reg-
larly associated with asthma in murine models [21,45,60].
lthough no human orthologues have been identiﬁed for Ym1
nd Ym2, other human chitinases have been demonstrated to
e involved in the pathogenesis of allergic disease and COPD.
In summary, drawing general conclusions from common
dentiﬁed proteins is challenging, because of the variety of
ouse strains, tissues and treatment protocols (difference in
iming, dosage and duration) that are used to induce asthma
r COPD (e.g. acute versus chronic). In addition, substantial
ifferences in physiology between mice and man  set hurdles
n extrapolating the results obtained from murine models to
umans.
.  Future
he rationale for choosing proteomics approaches, is to
iscover novel target proteins as biomarkers for disease iden-
iﬁcation, as well as possible new markers with the focus
n reﬁning treatment. Although different proteins are high-
ighted in Tables 1 and 2 that could be linked with the
henotypical characteristics of asthma or COPD in murine
odels and humans, functional biological validation – specif-
cally for murine studies - is nearly always lacking, thereby
ndicating the long way that is still to go in proteomics
iomarker research. One exception is the 2D-DIGE study of
ung tissue of Calvo et al. [24], who discovered the involve-
ent of a 78 kDa glucose-regulated protein precursor (Grp78) ( 2 0 1 4 ) 101–112 109
in OVA-induced asthma in mice. They silenced down  the gene
responsible for this protein using anti-Grp78 siRNA treatment
in OVA-sensitized and challenged mice, resulting in decreased
airway hyperreactivity (AHR) and eosinophilic inﬂammation.
This type of validation is valuable in determining the biolog-
ical relevance of the studied proteins as possible therapeutic
targets. On the other hand, proteomics studies are often used
to screen for markers of disease. Clinically useful biomarkers
would provide earlier and better diagnosis of patients, permit-
ting treatments to be initiated in early stages of the disease,
when the chance of success is greatest [96,97]. Several pro-
teins such as ferritin, transferrin and calcyclin were proposed
as general markers of lung disease [23,37]. As already indi-
cated, Hur et al. described ferritin and transferrin as possible
biomarkers of MDI-induced asthma, but Sastre et al. could not
verify these markers. Moreover, ferritin and transferrin are
involved in a broad range of biological processes, limiting their
use as speciﬁc biomarkers. More efforts should be focused
to ﬁnd disease-speciﬁc, unique biomarkers for lung diseases.
Perhaps future efforts should be less dedicated to known pro-
teins found differentially in these studies, but more  to explore
the proteins with unknown ontology. This could lead to really
novel and innovating biomarkers and perhaps also therapeu-
tic targets.
Furthermore, current state-of-the-art diagnosis and man-
agement schemes of asthma are suboptimal since the
incidence of asthma has risen by 250% over the last two
decades [16]. There is an urgent need for early diagnosis since
asthma generally starts early during childhood. Occupational
asthma often is exclusively related to exposures on the work
ﬂoor and thereby only develops at a later stage of life. However,
the onset of allergic OA is always preceded by a complaints-
free latency period in which workers are getting sensitized, as
a result of complex immunological and molecular processes
that are not identiﬁed by currently used diagnostic tools but
which could be picked up by ‘-omics’ techniques.
In addition, peptide hormones, neuropeptides, cytokines
and chemokines are involved in the regulation of numer-
ous physiological processes and the onset, maintenance and
progression of diseases such as asthma. These peptides are
generally not detected by proteomics techniques either due
to their size (<20 kDa) or to their low abundance and there-
fore are a yet unexplored pool of possible new biomarkers
[98]. Peptidomics techniques, using a combination of liquid
chromatography and mass spectrometry can be used to iden-
tify peptides. Nonetheless, quantitative peptidomics is still a
major challenge.
8.  Conclusion
There is an increasing trend in the use of proteomics to
explore new biomarkers of asthma or COPD. Although dif-
ferent murine models have been developed to study these
lung diseases, and proteomics studies have been performed,
functional validation of the identiﬁed candidate biomarkers
or translation into clinical studies is often lacking. Shifting
the focus from disease toward the early events during disease
manifestation (e.g. sensitization) and the investigation of
peptides as a yet unexplored pool of interesting biomarkers
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would bear great potential in the identiﬁcation of possible
new, clinically useful biomarkers.
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